Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

Low Dose Olanzapine in the Prevention and Treatment of Carboplatin Induced Nausea and Vomiting: A Prospective Clinical Randomized Controlled Trial

Author(s): Yun An, Zewei Zhang, Min Gu, Juan Zhao, Caihong Jiang, Lanzhen Zhao, Ying Jiang, Hui Li, Guang Liu, Gaowa Jin* and Quanfu Li*

Volume 29, Issue 23, 2023

Published on: 07 August, 2023

Page: [1867 - 1874] Pages: 8

DOI: 10.2174/1381612829666230804114538

Price: $65

Abstract

Objective: This study aimed to determine the effectiveness and safety of 5 mg olanzapine (OLZ) in preventing vomiting and nausea caused by carboplatin chemotherapy.

Methods: All patients with malignant tumors (n = 113) who underwent Carboplatin (AUC ≥ 5) treatment were randomly categorized into two groups: the standard group (n = 57) and the OLZ regimen (n = 56). The major endpoints of the trial were the TC (total control) between two groups during the OP (Overall phase, 0-120 hours), DP (delayed phase, 25-120 hours), and AP (acute phase, 0-24 hours). The secondary endpoints were the CR (complete response) and TP (total protection) during AP, OP, and DP. The time of first vomiting was compared between the two groups using Kaplan-Meier curves. The impact of CINV on the quality of life was assessed by the Functional Living Index-Emesis (FLIE). OLZ-related side effects were also recorded.

Results: (1) The primary endpoint TC rates were more favorable in the OLZ regimen group than in the standard group during the AP 87.50% (49/56) vs. 63.15% (36/57) P = 0.003, OP 62.50% (35/56) vs. 31.57% (18/57) P = 0.001, and DP 64.28% (36/56) vs. 33.33% (19/57) P = 0.001. (2) The secondary endpoints TP were 82.14% (46/56) vs. 63.15% (36/57), P = 0.024, 83.92% (47/56) vs. 63.15% (36/57). P = 0.012 during the DP and OP. There was no statistical significance during AP between the two groups. The CR rates were not statistically different between the two groups during the three periods, P > 0.05; (3) The first vomiting time in the OLZ group was delayed compared with the standard group (P = 0.248). The effect on life quality (score ≥ 108) assessed by FLIE was 62.50% vs. 43.48% between the two groups, P < 0.05. The primary side effects of OLZ are fatigue (85%) and somnolence (75%). The primary side effects of the standard group are fatigue (77%) and loss of appetite (85%).

Conclusion: The 5 mg OLZ-based triple antiemetic regimen is effective and safe in preventing vomiting and nausea induced by Carboplatin.

« Previous Next »
[1]
Woopen H, Richter R, Chekerov R, et al. Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213. Support Care Cancer 2020; 28(1): 73-8.
[http://dx.doi.org/10.1007/s00520-019-04778-1] [PMID: 30980260]
[2]
Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27 (Suppl. 5): v119-33.
[http://dx.doi.org/10.1093/annonc/mdw270] [PMID: 27664248]
[3]
Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017; 35(28): 3240-61.
[http://dx.doi.org/10.1200/JCO.2017.74.4789] [PMID: 28759346]
[4]
NCCN clinical practice guidelines in oncology: Antiemesis Version 2. 2017. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
[5]
Qing SK, Li J, Wang JJ, Zhang L, Ma J, Pan HM, et al. Guidelines of Chinese Society of Clinical Oncology: Prevention and treatment of nausea and vomiting caused by antitumor therapies. Cancer Commun 2019; 41(8): 747-95.
[6]
Chelkeba L, Gidey K, Mamo A, Yohannes B, Matso T, Melaku T. Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Pharm Pract 2017; 15(1): 877.
[http://dx.doi.org/10.18549/PharmPract.2017.01.877] [PMID: 28503222]
[7]
Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011; 9(5): 188-95.
[http://dx.doi.org/10.1016/j.suponc.2011.05.002] [PMID: 22024310]
[8]
Tan L, Liu J, Liu X, et al. Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 2009; 28(1): 131.
[http://dx.doi.org/10.1186/1756-9966-28-131] [PMID: 19775450]
[9]
Yanai T, Iwasa S, Hashimoto H, et al. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 2018; 23(2): 382-8.
[http://dx.doi.org/10.1007/s10147-017-1200-4] [PMID: 29039073]
[10]
Cai B, Elmer M, Lindley C, Pearson JD, Martin AR, Horgan K. Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index?Emesis (FLIE) with 5-day recall. Support Care Cancer 2003; 11(8): 522-7.
[http://dx.doi.org/10.1007/s00520-003-0482-4] [PMID: 12827483]
[11]
Decker GM, DeMeyer ES, Kisko DL. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 2006; 4(1): 35-41, 52.
[PMID: 16444851]
[12]
Martin AR, Carides AD, Pearson JD, et al. Functional relevance of antiemetic control. Eur J Cancer 2003; 39(10): 1395-401.
[http://dx.doi.org/10.1016/S0959-8049(03)00299-5] [PMID: 12826042]
[13]
Iihara H, Shimokawa M, Hayashi T, et al. A nationwide, multicenter registry study of antiemesis for carboplatin-based chemotherapy-induced nausea and vomiting in Japan. Oncologist 2020; 25(2): e373-80.
[http://dx.doi.org/10.1634/theoncologist.2019-0292] [PMID: 32043774]
[14]
Yang T, Liu Q, Lu M, Ma L, Zhou Y, Cui Y. Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol 2017; 83(7): 1369-79.
[http://dx.doi.org/10.1111/bcp.13242] [PMID: 28112422]
[15]
Iihara H, Shimokawa M, Gomyo T, et al. Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial. BMJ Open 2019; 9(7): e028056.
[http://dx.doi.org/10.1136/bmjopen-2018-028056] [PMID: 31278102]
[16]
Sakai C, Shimokawa M, Iihara H, et al. Low-dose olanzapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic malignancies: A prospective multicenter phase II trial. Oncologist 2021; 26(6): e1066-72.
[http://dx.doi.org/10.1002/onco.13772] [PMID: 33811782]
[17]
Sekine I, Segawa Y, Kubota K, Saeki T. Risk factors of chemotherapy-induced nausea and vomiting: Index for personalized antiemetic prophylaxis. Cancer Sci 2013; 104(6): 711-7.
[http://dx.doi.org/10.1111/cas.12146] [PMID: 23480814]
[18]
Jin Y, Jin G, Zhao J, et al. Clinical observation of gene polymorphism of olanzapine or aprepitant in prevention of CINV. Pharm Genomics Pers Med 2021; 14: 867-75.
[http://dx.doi.org/10.2147/PGPM.S317229] [PMID: 34290520]
[19]
Matsui R, Suzuki K, Takiguchi T, et al. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study. BMC Pharmacol Toxicol 2020; 21(1): 72.
[http://dx.doi.org/10.1186/s40360-020-00445-y] [PMID: 33023657]
[20]
Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer. J Clin Oncol 2018; 36(28): 2872-8.
[http://dx.doi.org/10.1200/JCO.2018.79.0006] [PMID: 30125216]
[21]
Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol 2014; 32(2): 101-6.
[http://dx.doi.org/10.1200/JCO.2013.51.4547] [PMID: 24323030]
[22]
Ito Y, Karayama M, Inui N, et al. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer 2014; 84(3): 259-64.
[http://dx.doi.org/10.1016/j.lungcan.2014.03.017] [PMID: 24746177]
[23]
Watanabe Y, Saito Y, Mitamura T, Takekuma Y, Sugawara M. Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer. J Pharm Health Care Sci 2021; 7(1): 21.
[http://dx.doi.org/10.1186/s40780-021-00204-z] [PMID: 34059157]
[24]
Rumyantsev A, Glazkova E, Nasyrova R, et al. Olanzapine (OLN) versus aprepitant (APR) in patients receiving high-emetogenic chemotherapy: Final results of randomized phase II trial. J Clin Oncol 2019; 37(15_suppl): 11504.
[http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.11504]
[25]
Ithimakin S, Theeratrakul P, Laocharoenkiat A, et al. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. Support Care Cancer 2020; 28(11): 5335-42.
[http://dx.doi.org/10.1007/s00520-020-05380-6] [PMID: 32128615]
[26]
Moudi S, Nikbakhsh N, Sadeghi MV, et al. Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy. J Res Med Sci 2016; 21(1): 88.
[http://dx.doi.org/10.4103/1735-1995.192504] [PMID: 28163734]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy